rosiglitazone has been researched along with Diabetic Angiopathies in 62 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 48 (77.42) | 29.6817 |
| 2010's | 13 (20.97) | 24.3611 |
| 2020's | 1 (1.61) | 2.80 |
| Authors | Studies |
|---|---|
| Bacha, F; Braffett, BH; Gidding, SS; Gubitosi-Klug, RA; Levitt Katz, LE; Shah, AS; Shah, RD; Tryggestad, JB; Urbina, EM | 1 |
| Duan, Y; Fu, X; Gao, H; Liu, Y; Xie, C; Xie, H; Yuan, H; Zhou, M | 1 |
| Argraves, WS; Cangemi, C; Christensen, MM; Gram, J; Grodum, E; Henriksen, JE; Rasmussen, LM; Skov, V; Sørensen, D | 1 |
| McCarthy, M | 1 |
| Ciaraldi, TP; Samad, F; Wang, J | 1 |
| Lehmann, DF; Lohray, BB | 1 |
| Furberg, CD; Singh, S | 1 |
| Cannon, CP; Fitzgerald, PJ; Gerstein, HC; Kolatkar, NS; Kravitz, BG; Nesto, RW; Ratner, RE; Serruys, PW; Van Es, GA; Zalewski, A | 1 |
| Abraira, C; Davis, SN; Duckworth, W; Emanuele, N; Goldman, S; Hayward, R; Henderson, WG; Huang, GD; Marks, J; McCarren, M; Moritz, T; Reaven, PD; Reda, D; Vitek, ME; Warren, SR; Zieve, FJ | 1 |
| Abdullah, SM; Ayers, CR; McGavock, JM; McGuire, DK; See, R; Snell, PG; Szczepaniak, LS | 1 |
| Bruskina, O; Byrne, RM; Cagliero, E; Crimins, J; Daher, M; Finn, AV; Gold, HK; Hendricks, M; John, MC; Kastrati, A; Nadelson, J; Oh, JS; Palacios, I; Schömig, A | 1 |
| Arrigain, S; Atreja, A; Jain, A; Kattan, MW; Pantalone, KM; Wells, BJ; Yu, C; Zimmerman, RS | 1 |
| Krentz, A | 1 |
| Albert, JM; Bailie, GR; Blayney, MJ; Goodkin, DA; Pisoni, RL; Port, FK; Ramirez, SP; Tentori, F; Wolfe, RA; Young, EW | 1 |
| Lebovitz, HE | 1 |
| Barnett, AH | 1 |
| Simon, D | 1 |
| Fisher, M | 1 |
| Booth, A; Konstantinidis, A; Lambley, RG; Vahdani, K | 1 |
| Curcin, V; Elliott, P; Hughes, RI; Khunti, K; Little, MP; Majeed, A; Millett, CJ; Molokhia, M; Ng, A; Tzoulaki, I; Wilkins, MR | 1 |
| Guo, X; Karathanasis, SK; Kassab, GS; Lu, X; Onyia, JE; Peterson, RG; Zimmerman, KM | 1 |
| Abdullah, SM; Ayers, CR; de Lemos, JA; Drazner, MH; Khera, A; McGavock, J; McGuire, DK; See, R; Snell, PG; Szczepaniak, LS | 1 |
| Bloomgarden, Z | 1 |
| Chilton, RJ; Schernthaner, G | 1 |
| Gautier, JF; Lesven, S; Maréchaud, R | 1 |
| Brugaletta, S; García-García, HM; Garg, S; Huang, C; Kolatkar, NS; Kravitz, BG; Miller, DM; Morocutti, G; Nesto, RW; Ratner, RE; Serruys, PW | 1 |
| Wilding, JP | 1 |
| Aubert, JP; Bouée, S; Detournay, B; Fontbonne, A; Guillausseau, PJ; Halimi, S; Nachit, F | 1 |
| Abo-Warda, SM; El-Bassossy, HM; Fahmy, A | 1 |
| Home, P | 1 |
| Chen, H; Freed, MI; Greenberg, AS; Haffner, SM; Weston, WM; Williams, K | 1 |
| Cohen, H; Dvir, A; Gerber, Y; Harats, D; Levi, Z; Levkovitz, H; Ravid, M; Rhachmani, R; Shaish, A; Trestman, S; Yacov, N | 1 |
| Bakris, G; Freed, MI; Heise, M; Porter, LE; Viberti, G; Weston, WM | 1 |
| Viberti, GC | 1 |
| Görtz, A; Lander, T; Reblin, T; Seidel, D; Stein, D | 1 |
| Brizolara, A; Fitzgerald, P; Osman, A; Otero, J; Stouffer, G; Uretsky, BF; Waxman, S | 1 |
| Bosch, J; Gerstein, HC; Holman, R; Pogue, J; Yusuf, S | 1 |
| Ahn, CW; Cha, BS; Choi, D; Choi, SH; Jang, Y; Kim, SK; Ko, YG; Lee, HC; Lim, SK | 1 |
| Baldeweg, S; Baldi, S; Casolaro, A; Ferrannini, E; Natali, A; Sironi, AM; Toschi, E; Yudkin, JS | 1 |
| Fonseca, VA; Jawa, AA | 1 |
| Guan, Y; Jin, N; Mao, J; Wang, G; Wang, X; Wei, J | 1 |
| Cho, L; Lewis, BE; Leya, FS; Steen, LH | 1 |
| Gil-Ortega, I; Kaski, JC; Marzoa-Rivas, R; Ríos-Vázquez, R | 1 |
| Bošanská, L; Doležalová, R; Haluzík, M; Haluzík, MM; Kasalová, Z; Lacinová, Z; Stulc, T | 1 |
| Balasubramani, M; Capps, N; Milles, J; Ramachandran, S; Shetty, C | 1 |
| Berglund, G; Hedblad, B; Janzon, L; Nilsson, P; Zambanini, A | 1 |
| Jezior, MR; Langley, RW; Stocker, DJ; Taylor, AJ; Vigersky, RA | 1 |
| Hedner, T; Kjeldsen, SE; Narkiewicz, K; Oparil, S | 1 |
| Abdul Rahman, AR; Ismail, AA; Ismail, SB; Naing, NN; Rahman, S | 1 |
| Bahlmann, FH; Besler, C; Doerries, C; Drexler, H; Fliser, D; Haller, H; Horváth, T; Kirchhoff, N; Landmesser, U; Limbourg, A; Limbourg, F; Müller, M; Schulz, S; Sorrentino, SA | 1 |
| Hanefeld, M | 1 |
| Chin-Dusting, J; Cooper, ME; Jandeleit-Dahm, KA; Kling, D; Mizrahi, J; Murphy, A; Sebokova, E; Sheehy, K; Tikellis, C; Woollard, KJ | 1 |
| Honisett, SY; Komesaroff, PA; Stojanovska, L | 1 |
| Bégaud, B; Bernard, MH; Eschwège, E; Grimaldi, A; Oppert, JM; Pouchain, D; Slama, G | 1 |
| Alevizos, M; Angelopoulou, N; Iliadis, F; Kadoglou, NP; Liapis, CD; Perrea, D | 1 |
| Bauersachs, J; Thum, T | 1 |
| Chilton, R; Sulistio, MS; Thukral, N; Zion, A | 1 |
| Matthews, DR | 1 |
14 review(s) available for rosiglitazone and Diabetic Angiopathies
| Article | Year |
|---|---|
Thiazolidinediones: effects on the development and progression of type 2 diabetes and associated vascular complications.
Topics: Diabetes Mellitus, Type 2; Diabetic Angiopathies; Disease Progression; Humans; Hypoglycemic Agents; Pioglitazone; Rosiglitazone; Thiazolidinediones; Vascular Diseases | 2009 |
Redefining the role of thiazolidinediones in the management of type 2 diabetes.
Topics: Administration, Oral; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Pioglitazone; Rosiglitazone; Thiazolidinediones; Treatment Outcome | 2009 |
Improving cardiovascular risk--applying evidence-based medicine to glucose-lowering therapy with thiazolidinediones in patients with type 2 diabetes.
Topics: Atherosclerosis; Biomarkers; Blood Glucose; Carotid Artery Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Endothelium, Vascular; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipids; Pioglitazone; Randomized Controlled Trials as Topic; Recurrence; Risk Factors; Rosiglitazone; Stents; Thiazolidinediones; Tunica Intima; Tunica Media; Vascular Resistance | 2009 |
Cardiovascular risk and thiazolidinediones--what do meta-analyses really tell us?
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Humans; Male; Meta-Analysis as Topic; Randomized Controlled Trials as Topic; Risk Factors; Rosiglitazone; Thiazolidinediones | 2010 |
Treatment of type 2 diabetes: New clinical studies and effects of GLP-1 on macrovascular complications.
Topics: Animals; Coronary Artery Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Glucagon-Like Peptide 1; Heart Diseases; Humans; Hypoglycemic Agents; Risk Factors; Rosiglitazone; Thiazolidinediones | 2010 |
PPAR agonists for the treatment of cardiovascular disease in patients with diabetes.
Topics: Blood Glucose; Cardiovascular Diseases; Clinical Trials, Phase II as Topic; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dyslipidemias; Humans; Hypoglycemic Agents; Oxazoles; Peroxisome Proliferator-Activated Receptors; PPAR alpha; PPAR gamma; Rosiglitazone; Thiazolidinediones; Thiophenes; Treatment Outcome | 2012 |
Cardiovascular disease and oral agent glucose-lowering therapies in the management of type 2 diabetes.
Topics: Administration, Oral; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dipeptidyl-Peptidase IV Inhibitors; Female; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Myocardial Infarction; Randomized Controlled Trials as Topic; Risk Reduction Behavior; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones; United Kingdom | 2012 |
Rosiglitazone: potential beneficial impact on cardiovascular disease.
Topics: Albuminuria; Arteriosclerosis; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Hyperglycemia; Hyperlipidemias; Hypertension; Hypoglycemic Agents; Insulin Resistance; Obesity; Risk Factors; Rosiglitazone; Thiazoles; Thiazolidinediones | 2003 |
Role of insulin secretagogues and insulin sensitizing agents in the prevention of cardiovascular disease in patients who have diabetes.
Topics: Angioplasty, Balloon, Coronary; Animals; Biguanides; Blood Pressure; Chromans; Diabetic Angiopathies; Endothelium, Vascular; Fibrinolysis; Humans; Hypoglycemic Agents; Metformin; Oxidative Stress; Postprandial Period; Risk Factors; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones; Troglitazone | 2005 |
Peroxisome proliferator-activated receptor-gamma agonists for management and prevention of vascular disease in patients with and without diabetes mellitus.
Topics: Atherosclerosis; Blood Platelets; Coronary Disease; Diabetic Angiopathies; Endothelium, Vascular; Humans; Hypoglycemic Agents; Inflammation; Insulin Resistance; Pioglitazone; PPAR gamma; Rosiglitazone; Thiazolidinediones | 2006 |
The question of whether diabetes and its cardiovascular risks can be prevented: a realistic DREAM?
Topics: Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus; Diabetic Angiopathies; Humans; Premedication; Ramipril; Rosiglitazone; Thiazolidinediones; Treatment Outcome | 2006 |
Cardiovascular benefits and safety profile of acarbose therapy in prediabetes and established type 2 diabetes.
Topics: Acarbose; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Hypertension; Hypoglycemic Agents; Metformin; Prediabetic State; Rosiglitazone; Safety; Thiazolidinediones | 2007 |
The anti-atherogenic effects of thiazolidinediones.
Topics: Atherosclerosis; Biomarkers; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Endothelium, Vascular; Humans; Hypolipidemic Agents; Kidney; Lipid Metabolism; Models, Biological; Pioglitazone; Postmenopause; Rosiglitazone; Thiazolidinediones | 2007 |
PPARgamma agonists and coronary atherosclerosis.
Topics: Animals; Coronary Artery Disease; Coronary Restenosis; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Fatty Acids, Nonesterified; Humans; Hypoglycemic Agents; Insulin Resistance; Pioglitazone; PPAR gamma; Randomized Controlled Trials as Topic; Rosiglitazone; Stents; Thiazolidinediones; Triglycerides | 2008 |
20 trial(s) available for rosiglitazone and Diabetic Angiopathies
| Article | Year |
|---|---|
Circulating adhesion molecules and associations with HbA1c, hypertension, nephropathy, and retinopathy in the Treatment Options for type 2 Diabetes in Adolescent and Youth study.
Topics: Adolescent; Age of Onset; Cell Adhesion Molecules; Child; Combined Modality Therapy; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Diabetic Retinopathy; Drug Therapy, Combination; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Hypertension; Male; Metformin; Risk Reduction Behavior; Rosiglitazone | 2020 |
Metformin, but not rosiglitazone, attenuates the increasing plasma levels of a new cardiovascular marker, fibulin-1, in patients with type 2 diabetes.
Topics: Adult; Aged; Biomarkers; Blood Glucose; Calcium-Binding Proteins; Cardiovascular System; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Prospective Studies; Rosiglitazone; Thiazolidinediones; Up-Regulation | 2014 |
Tissue factor expression in obese type 2 diabetic subjects and its regulation by antidiabetic agents.
Topics: Adult; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Gene Expression Regulation; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Obesity; Rosiglitazone; Thiazolidinediones; Thromboplastin | 2015 |
Assessment on the Prevention of Progression by Rosiglitazone on Atherosclerosis in diabetes patients with Cardiovascular History (APPROACH): study design and baseline characteristics.
Topics: Adult; Aged; Coronary Artery Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Disease Progression; Double-Blind Method; Female; Glipizide; Humans; Hypoglycemic Agents; Male; Middle Aged; Risk Factors; Rosiglitazone; Thiazolidinediones; Ultrasonography, Interventional | 2008 |
Glucose control and vascular complications in veterans with type 2 diabetes.
Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Neuropathies; Drug Therapy, Combination; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Kaplan-Meier Estimate; Male; Metformin; Middle Aged; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones; United States; Veterans | 2009 |
The effect of rosiglitazone on integrated cardiovascular performance, cardiac structure, function and myocardial triglyceride: trial design and rationale.
Topics: Adult; Cardiovascular Diseases; Cardiovascular Physiological Phenomena; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Exercise Test; Fibrinolytic Agents; Heart; Humans; Hypoglycemic Agents; Myocardium; Oxygen Consumption; Reproducibility of Results; Research Design; Rosiglitazone; Thiazolidinediones; Triglycerides; Young Adult | 2009 |
Predictive factors for in-stent late loss and coronary lesion progression in patients with type 2 diabetes mellitus randomized to rosiglitazone or placebo.
Topics: Aged; Angioplasty, Balloon, Coronary; Biomarkers; Coronary Angiography; Coronary Restenosis; Coronary Stenosis; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Disease Progression; Double-Blind Method; Female; Humans; Male; Middle Aged; Predictive Value of Tests; Prognosis; Rosiglitazone; Stents; Thiazolidinediones; Vasodilator Agents | 2009 |
Randomized comparison of the effects of rosiglitazone vs. placebo on peak integrated cardiovascular performance, cardiac structure, and function.
Topics: Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Exercise Test; Female; Humans; Hypoglycemic Agents; Magnetic Resonance Angiography; Male; Middle Aged; Oxygen Consumption; Plasma Volume; Rosiglitazone; Stroke Volume; Thiazolidinediones; Treatment Outcome | 2010 |
Evaluation of in-stent restenosis in the APPROACH trial (Assessment on the Prevention of Progression by Rosiglitazone On Atherosclerosis in diabetes patients with Cardiovascular History).
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Angioplasty, Balloon, Coronary; Coronary Angiography; Coronary Artery Disease; Coronary Restenosis; Coronary Vessels; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Drug-Eluting Stents; Female; Glipizide; Humans; Hyperplasia; Hypoglycemic Agents; Male; Metals; Middle Aged; Neointima; Predictive Value of Tests; Prospective Studies; Prosthesis Design; Rosiglitazone; Stents; Thiazolidinediones; Time Factors; Treatment Outcome; Ultrasonography, Interventional | 2012 |
Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus.
Topics: Biomarkers; Body Weight; C-Reactive Protein; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Female; Humans; Interleukin-6; Leukocyte Count; Male; Matrix Metalloproteinase 9; Middle Aged; Receptors, Cytoplasmic and Nuclear; Risk Factors; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors | 2002 |
Rosiglitazone reduces urinary albumin excretion in type II diabetes.
Topics: Administration, Oral; Aged; Albuminuria; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Kidney Function Tests; Male; Middle Aged; Reference Values; Rosiglitazone; Sensitivity and Specificity; Thiazoles; Thiazolidinediones; Treatment Outcome | 2003 |
Effect of rosiglitazone on restenosis after coronary stenting in patients with type 2 diabetes.
Topics: Administration, Oral; Adult; Aged; Cardiovascular Agents; Coronary Angiography; Coronary Restenosis; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Plasminogen Activator Inhibitor 1; Rosiglitazone; Stents; Thiazolidinediones | 2004 |
Rationale, design and recruitment characteristics of a large, simple international trial of diabetes prevention: the DREAM trial.
Topics: Adult; Aged; Antihypertensive Agents; Body Mass Index; Body Size; Diabetes Mellitus; Diabetes, Gestational; Diabetic Angiopathies; Female; Humans; Hypoglycemic Agents; Life Style; Male; Middle Aged; Patient Selection; Pregnancy; Ramipril; Rosiglitazone; Thiazolidinediones | 2004 |
Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes.
Topics: Adult; Aged; Coronary Angiography; Coronary Restenosis; Coronary Stenosis; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Rosiglitazone; Stents; Thiazolidinediones; Treatment Outcome; Vasodilator Agents | 2004 |
Haematocrit, type 2 diabetes, and endothelium-dependent vasodilatation of resistance vessels.
Topics: Acetylcholine; Blood Flow Velocity; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dose-Response Relationship, Drug; Endothelium, Vascular; Female; Forearm; Hematocrit; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitroprusside; Rosiglitazone; Thiazolidinediones; Vascular Resistance; Vasodilation; Vasodilator Agents | 2005 |
Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone reduces clinical inflammatory responses in type 2 diabetes with coronary artery disease after coronary angioplasty.
Topics: Aged; Angioplasty, Balloon, Coronary; C-Reactive Protein; Chemokine CCL2; Chemokines; Coronary Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Humans; Inflammation; Lipopolysaccharides; Male; Middle Aged; Monocytes; PPAR gamma; Rosiglitazone; Thiazolidinediones | 2005 |
Rosiglitazone and carotid IMT progression rate in a mixed cohort of patients with type 2 diabetes and the insulin resistance syndrome: main results from the Rosiglitazone Atherosclerosis Study.
Topics: Adult; Aged; Aged, 80 and over; Atherosclerosis; Carotid Artery Diseases; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Disease Progression; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Middle Aged; Rosiglitazone; Sweden; Thiazolidinediones; Tunica Intima | 2007 |
A randomized trial of the effects of rosiglitazone and metformin on inflammation and subclinical atherosclerosis in patients with type 2 diabetes.
Topics: Aged; Atherosclerosis; C-Reactive Protein; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Disease Progression; Female; Humans; Hypoglycemic Agents; Inflammation; Male; Metformin; Middle Aged; Multivariate Analysis; Rosiglitazone; Thiazolidinediones; Tunica Intima; Tunica Media; Vasodilator Agents | 2007 |
Effect of rosiglitazone/ramipril on preclinical vasculopathy in newly diagnosed, untreated diabetes and IGT patients: 1-year randomised, double-blind, placebo-controlled study.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Arteries; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Glucose Intolerance; Humans; Hypoglycemic Agents; Middle Aged; Pulsatile Flow; Ramipril; Rosiglitazone; Stroke Volume; Thiazolidinediones; Vascular Diseases | 2007 |
Beneficial effects of rosiglitazone on novel cardiovascular risk factors in patients with Type 2 diabetes mellitus.
Topics: Adiponectin; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Exercise; Female; Humans; Hypoglycemic Agents; Male; Metalloproteases; Middle Aged; Regression Analysis; Rosiglitazone; Thiazolidinediones | 2008 |
28 other study(ies) available for rosiglitazone and Diabetic Angiopathies
| Article | Year |
|---|---|
Comparison of efficacy of SHENQI compound and rosiglitazone in the treatment of diabetic vasculopathy analyzing multi-factor mediated disease-causing modules.
Topics: Animals; Aorta, Abdominal; Cardiovascular Agents; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Disease Models, Animal; Drugs, Chinese Herbal; Gene Expression; Humans; Hypoglycemic Agents; Male; Medicine, Chinese Traditional; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Phytotherapy; Rosiglitazone; Signal Transduction | 2018 |
US regulators relax restrictions on rosiglitazone.
Topics: Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Humans; Hypoglycemic Agents; Male; Myocardial Infarction; Practice Patterns, Physicians'; Product Surveillance, Postmarketing; Rosiglitazone; Thiazolidinediones; United States; United States Food and Drug Administration | 2013 |
A lesson in moderation: applying pharmacodynamics to clarify the relationship between thiazolidinediones and adverse vascular outcomes in type 2 diabetes.
Topics: Atherosclerosis; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Hypoglycemic Agents; PPAR gamma; Rosiglitazone; Thiazolidinediones | 2008 |
Thiazolidinediones and cardiovascular outcomes in type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Diabetic Angiopathies; Heart Failure; Humans; Myocardial Ischemia; Pioglitazone; Rosiglitazone; Thiazolidinediones; Treatment Outcome | 2009 |
The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis.
Topics: Angiotensin-Converting Enzyme Inhibitors; Coronary Artery Bypass; Coronary Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Heart Failure; Humans; Hypoglycemic Agents; Male; Metformin; Multivariate Analysis; Proportional Hazards Models; Retrospective Studies; Risk Factors; Rosiglitazone; Smoking; Sulfonylurea Compounds; Survival Analysis; Survivors; Thiazolidinediones | 2009 |
Rosiglitazone is associated with mortality in chronic hemodialysis patients.
Topics: Aged; Cardiovascular Diseases; Diabetic Angiopathies; Diabetic Nephropathies; Female; Hospitalization; Humans; Hypoglycemic Agents; Kidney Failure, Chronic; Male; Middle Aged; Proportional Hazards Models; Renal Dialysis; Rosiglitazone; Thiazolidinediones | 2009 |
Glycaemic control and vascular complications in type 2 diabetes: new observations and clinical significance.
Topics: Aged; Comorbidity; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Middle Aged; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazolidinediones; Treatment Outcome | 2008 |
Rosiglitazone.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Europe; Humans; Hypoglycemic Agents; Meta-Analysis as Topic; Rosiglitazone; Societies, Medical; Thiazolidinediones; United States | 2009 |
Rosiglitazone and pioglitazone. Beware macular oedema.
Topics: Diabetic Angiopathies; Diabetic Nephropathies; Heart Failure; Humans; Hypoglycemic Agents; Macular Edema; Pioglitazone; Rosiglitazone; Thiazolidinediones | 2009 |
Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database.
Topics: Administration, Oral; Aged; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Fractures, Bone; Heart Failure; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Myocardial Infarction; Pioglitazone; Retrospective Studies; Risk Factors; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones | 2009 |
Rosiglitazone reverses endothelial dysfunction but not remodeling of femoral artery in Zucker diabetic fatty rats.
Topics: Adiposity; Animals; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Disease Models, Animal; Dose-Response Relationship, Drug; Endothelium, Vascular; Femoral Artery; Hypoglycemic Agents; Matrix Metalloproteinase 9; Myography; Nitric Oxide Synthase Type III; Pancreatic Elastase; Rats; Rats, Zucker; Receptors, Adrenergic, alpha; Rosiglitazone; Thiazolidinediones; Time Factors; Triglycerides; Vasoconstriction; Vasoconstrictor Agents; Vasodilation; Vasodilator Agents | 2010 |
Recent cardiovascular trials: what are the drivers of benefit and adverse effect?
Topics: Cardiovascular Diseases; Clinical Trials as Topic; Diabetic Angiopathies; Gliclazide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Insulin; Rosiglitazone; Thiazolidinediones | 2009 |
A real-life study of the use, effectiveness and tolerability of rosiglitazone in France: the AVANCE study.
Topics: Adult; Aged; Blood Glucose; Comorbidity; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; France; Glycated Hemoglobin; Humans; Hypercholesterolemia; Hypertension; Hypoglycemic Agents; Longitudinal Studies; Male; Medication Adherence; Middle Aged; Practice Patterns, Physicians'; Rosiglitazone; Smoking; Surveys and Questionnaires; Thiazolidinediones; Time Factors; Treatment Outcome | 2012 |
Rosiglitazone, a peroxisome proliferator-activated receptor γ stimulant, abrogates diabetes-evoked hypertension by rectifying abnormalities in vascular reactivity.
Topics: Animals; Blood Glucose; Blood Pressure; Blood Vessels; Calcium; Cholesterol; Diabetes Mellitus, Experimental; Diabetic Angiopathies; Glycation End Products, Advanced; Hypertension; Hypoglycemic Agents; In Vitro Techniques; Male; Nitric Oxide; Potassium Chloride; PPAR gamma; Rats; Rosiglitazone; Thiazolidinediones; Triglycerides | 2012 |
Rosiglitazone (PPARgamma-agonist) attenuates atherogenesis with no effect on hyperglycaemia in a combined diabetes-atherosclerosis mouse model.
Topics: Animals; Aortic Diseases; Apolipoproteins E; Arteriosclerosis; Blood Glucose; Cholesterol; Diabetes Mellitus, Experimental; Diabetic Angiopathies; Fibrinolytic Agents; Male; Mice; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Triglycerides | 2003 |
[Preventing infarct in the diabetic patient. Lowering blood glucose and HbA1c are not enough].
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Glucose Clamp Technique; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Myocardial Infarction; Rosiglitazone; Thiazoles; Thiazolidinediones | 2003 |
[Insulin resistance increases risk of infarct. Glitazone now approved also for monotherapy].
Topics: Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Approval; Germany; Humans; Hypoglycemic Agents; Insulin Resistance; Rosiglitazone; Survival Rate; Thiazolidinediones | 2003 |
Diabetes drug may also benefit blood vessels.
Topics: Angioplasty, Balloon, Coronary; Coronary Restenosis; Diabetic Angiopathies; Humans; Hypoglycemic Agents; Rosiglitazone; Thiazolidinediones | 2003 |
Protecting the heart while controlling blood sugar. New guidelines help define and refine the use of two diabetes drugs that could be a boon for people who also have heart disease.
Topics: Contraindications; Diabetes Mellitus; Diabetic Angiopathies; Heart Diseases; Heart Failure; Humans; Hypoglycemic Agents; Pioglitazone; Rosiglitazone; Thiazolidinediones | 2004 |
Thiazolidinediones do not reduce target vessel revascularization in diabetic patients undergoing percutaneous coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Cause of Death; Coronary Circulation; Coronary Stenosis; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Male; Middle Aged; Myocardial Infarction; Pioglitazone; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Retrospective Studies; Rosiglitazone; Stents; Survival Rate; Thiazolidinediones | 2005 |
Effect of PPAR-gamma agonist treatment on markers of endothelial dysfunction in patients with type 2 diabetes mellitus.
Topics: Adipose Tissue; Biomarkers; Body Mass Index; Diabetes Mellitus, Type 2; Diabetic Angiopathies; E-Selectin; Endothelium, Vascular; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Intercellular Adhesion Molecule-1; Lipids; Matrix Metalloproteinase 9; Middle Aged; Peroxidase; PPAR gamma; Resistin; Rosiglitazone; Thiazolidinediones; Vascular Cell Adhesion Molecule-1 | 2007 |
Paradoxical HDL-C reduction during rosiglitazone and fibrate treatment.
Topics: Anticholesteremic Agents; Atherosclerosis; Cholesterol, HDL; Clofibric Acid; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dyslipidemias; England; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Risk Factors; Rosiglitazone; Thiazolidinediones | 2007 |
Oxidant stress impairs in vivo reendothelialization capacity of endothelial progenitor cells from patients with type 2 diabetes mellitus: restoration by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone.
Topics: Aged; Animals; Blood Pressure; Carotid Arteries; Cholesterol; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Endothelial Cells; Endothelium, Vascular; Female; Humans; Male; Mice; Mice, Nude; Middle Aged; Models, Biological; Nitric Oxide; Oxidative Stress; PPAR gamma; Reference Values; Rosiglitazone; Stem Cells; Superoxides; Thiazolidinediones; Vasodilator Agents | 2007 |
Reduced plaque formation induced by rosiglitazone in an STZ-diabetes mouse model of atherosclerosis is associated with downregulation of adhesion molecules.
Topics: Animals; Aortic Diseases; Apolipoproteins E; Atherosclerosis; Cell Adhesion Molecules; Cells, Cultured; Chemokine CCL2; Diabetes Mellitus, Experimental; Diabetic Angiopathies; Disease Models, Animal; Down-Regulation; Endothelial Cells; Humans; Hypoglycemic Agents; Intercellular Adhesion Molecule-1; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; P-Selectin; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Umbilical Veins; Vascular Cell Adhesion Molecule-1; Vasculitis | 2008 |
[One-year follow-up in real clinical practice conditions of type 2 diabetic patients treated with rosiglitazone: the Avantage study].
Topics: Aged; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Follow-Up Studies; Humans; Hypoglycemic Agents; Middle Aged; Myocardial Infarction; Prospective Studies; Rosiglitazone; Thiazolidinediones; Time Factors | 2008 |
Letter by Thum et al regarding article, "Oxidant stress impairs in vivo reendothelialization capacity of endothelial progenitor cells from patients with type 2 diabetes mellitus: restoration by the peroxisome proliferator-activated receptor-gamma agonist
Topics: Biopterins; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Endothelial Cells; Humans; NADPH Oxidases; Nitric Oxide; Nitric Oxide Synthase; PPAR gamma; Rosiglitazone; Stem Cells; Thiazolidinediones; Vasodilator Agents | 2008 |
Guidance on rosiglitazone for type 2 diabetes mellitus.
Topics: Diabetes Mellitus, Type 2; Diabetic Angiopathies; England; Evidence-Based Medicine; Humans; Hypoglycemic Agents; Practice Guidelines as Topic; Rosiglitazone; Thiazoles; Thiazolidinediones | 2001 |
[Infarct prevention for diabetics. To lower blood sugar is not enough].
Topics: Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Fibrinolytic Agents; Humans; Hypoglycemic Agents; Insulin Resistance; Myocardial Infarction; Risk Factors; Rosiglitazone; Thiazoles; Thiazolidinediones; Vasodilator Agents | 2001 |